The Immunopeptidomics Ontology (ImPO)

Author:

Faria Daniel1,Eugénio Patrícia2ORCID,Contreiras Silva Marta2,Balbi Laura2,Bedran Georges3,Kallor Ashwin Adrian3,Nunes Susana2,Palkowski Aleksander3,Waleron Michal3,Alfaro Javier A3456,Pesquita Catia2

Affiliation:

1. INESC-ID, Instituto Superior Técnico, Universidade de Lisboa , Rua Alves Redol, 9, Lisboa 1000-029, Portugal

2. LASIGE, Faculdade de Ciências da Universidade de Lisboa , Campo Grande, Lisboa 1749-016, Portugal

3. International Centre for Cancer Vaccine Science, University of Gdansk , ul. Kładki 24, Gdańsk 80-822, Poland

4. Department of Biochemistry and Microbiology, University of Victoria , 3800 Finnerty Rd, Victoria, British Columbia, BC V8P 5C2, Canada

5. Institute for Adaptive and Neural Computation, School of Informatics, University of Edinburgh , Old College, South Bridge, Edinburgh, EH8 9YL, UK

6. The Canadian Association for Responsible AI in Medicine, Victoria , Canada

Abstract

Abstract The adaptive immune response plays a vital role in eliminating infected and aberrant cells from the body. This process hinges on the presentation of short peptides by major histocompatibility complex Class I molecules on the cell surface. Immunopeptidomics, the study of peptides displayed on cells, delves into the wide variety of these peptides. Understanding the mechanisms behind antigen processing and presentation is crucial for effectively evaluating cancer immunotherapies. As an emerging domain, immunopeptidomics currently lacks standardization—there is neither an established terminology nor formally defined semantics—a critical concern considering the complexity, heterogeneity, and growing volume of data involved in immunopeptidomics studies. Additionally, there is a disconnection between how the proteomics community delivers the information about antigen presentation and its uptake by the clinical genomics community. Considering the significant relevance of immunopeptidomics in cancer, this shortcoming must be addressed to bridge the gap between research and clinical practice. In this work, we detail the development of the ImmunoPeptidomics Ontology, ImPO, the first effort at standardizing the terminology and semantics in the domain. ImPO aims to encapsulate and systematize data generated by immunopeptidomics experimental processes and bioinformatics analysis. ImPO establishes cross-references to 24 relevant ontologies, including the National Cancer Institute Thesaurus, Mondo Disease Ontology, Logical Observation Identifier Names and Codes and Experimental Factor Ontology. Although ImPO was developed using expert knowledge to characterize a large and representative data collection, it may be readily used to encode other datasets within the domain. Ultimately, ImPO facilitates data integration and analysis, enabling querying, inference and knowledge generation and importantly bridging the gap between the clinical proteomics and genomics communities. As the field of immunogenomics uses protein-level immunopeptidomics data, we expect ImPO to play a key role in supporting a rich and standardized description of the large-scale data that emerging high-throughput technologies are expected to bring in the near future. Ontology URL: https://zenodo.org/record/10237571 Project GitHub: https://github.com/liseda-lab/ImPO/blob/main/ImPO.owl

Funder

Fundação para a Ciência e a Tecnologia

Fundacja na rzecz Nauki Polskiej

European Union’s Horizon 2020

Publisher

Oxford University Press (OUP)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3